Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TPST | Tempest Therapeutics, Inc.

Index	-	P/E	-	EPS (ttm)	-2.41	Insider Own	3.00%	Shs Outstand	14.10M	Perf Week	-20.50%
Market Cap	5.24M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.00%	Shs Float	12.67M	Perf Month	-37.57%
Income	-33.30M	PEG	-	EPS next Q	-0.57	Inst Own	71.30%	Short Float / Ratio	0.26% / 0.25	Perf Quarter	-67.75%
Sales	-	P/S	-	EPS this Y	58.60%	Inst Trans	-0.34%	Short Interest	0.03M	Perf Half Y	-72.36%
Book/sh	0.36	P/B	1.07	EPS next Y	21.60%	ROA	-75.00%	Target Price	15.67	Perf Year	-81.12%
Cash/sh	1.30	P/C	0.30	EPS next 5Y	-	ROE	-218.60%	52W Range	0.39 - 4.21	Perf YTD	-66.35%
Dividend	-	P/FCF	-	EPS past 5Y	60.50%	ROI	-	52W High	-90.82%	Beta	0.90
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	-	Gross Margin	-	52W Low	-0.77%	ATR	0.06
Employees	19	Current Ratio	2.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.03	Volatility	9.07% 11.07%
Optionable	No	Debt/Eq	2.10	EPS Q/Q	32.10%	Profit Margin	-	Rel Volume	1.57	Prev Close	0.48
Shortable	Yes	LT Debt/Eq	1.50	Earnings	Aug 10 AMC	Payout	-	Avg Volume	132.00K	Price	0.39
Recom	1.50	SMA20	-25.65%	SMA50	-46.42%	SMA200	-73.81%	Volume	207,412	Change	-19.12%

Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85%
05:00PM	Loading…
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire)
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
04:05PM	Loading…
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 09:00AM	Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer (GlobeNewswire)
Nov-08-22 08:00AM	Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.09%
Nov-02-22 08:00AM	Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting (GlobeNewswire) +8.72%
Oct-06-22 08:00AM	Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit (GlobeNewswire)
Sep-07-22 08:00AM	Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +11.40%
Aug-15-22 08:00AM	Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +15.81%
Jul-07-22 08:00AM	Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference (GlobeNewswire) +11.93%
Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance (GlobeNewswire)
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference (GlobeNewswire) -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting (GlobeNewswire)
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire) +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million (GlobeNewswire)
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting (GlobeNewswire)
04:00PM	Loading…
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference (GlobeNewswire)
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab (GlobeNewswire)
Nov-12-21 07:00AM	Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer (GlobeNewswire)
Nov-10-21 04:05PM	Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Nov-09-21 08:00AM	Tempest to Present at Two Upcoming Investor Conferences in November (GlobeNewswire)
Nov-08-21 08:00AM	Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495 (GlobeNewswire)
Oct-01-21 08:00AM	Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-20-21 08:00AM	Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche (GlobeNewswire)
Sep-13-21 08:00AM	Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target (GlobeNewswire)
Sep-09-21 04:01PM	Tempest to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-21 04:01PM	Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Aug-09-21 08:00AM	Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors (GlobeNewswire) +8.09%
Jul-09-21 08:00AM	Tempest to Participate in William Blair 2021 Biotech Focus Conference (GlobeNewswire) +49.38%
Jul-01-21 04:00PM	Tempest Announces Appointment of Christine Pellizzari to its Board of Directors (GlobeNewswire)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TPST | Tempest Therapeutics, Inc.

Upgrade your FINVIZ experience